All In Biotech

Drug Trial Radar · NCT05040932

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

A First-In-Human, Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of YH004 As A Single Agent And Combination With Toripalimab In Subjects With Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Dec 7, 2021

Primary completion

Jun 16, 2023

Study completion Jun 16, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of YH004, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Toripalimab) in the treatment of advanced solid tumors and relapsed or refractory non-Hodgkin Lymphoma.

Conditions

  • Cancer

Interventions

  • YH004Drug

    IV infusion once every 3 weeks (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs) including determination of DLTs and serious AEs (SAEs)Time frame: up to 24 months
  2. Maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D)Time frame: up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cabrini Health Limited

    Malvern East, Australia

  • Westmead Hospital

    Sydney, Australia

  • Southside Cancer Care Centre, School of Medicine, University of Wollongong

    Wollongong, Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.